TRX — Tissue Regenix Cashflow Statement
0.000.00%
- £24.99m
- £29.73m
- $29.49m
- 38
- 51
- 34
- 32
Annual cashflow statement for Tissue Regenix, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | fx Final | fx Final | Final | Final | Final |
Net Income/Starting Line | -9.77 | -13.1 | -5.14 | -2.83 | -1.67 |
Depreciation | |||||
Amortisation | |||||
Non-Cash Items | 2.91 | 9.22 | 1.54 | 1.01 | 1.97 |
Unusual Items | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | -2.99 | -3.77 | -0.468 | -0.616 | -0.239 |
Change in Accounts Receivable | |||||
Change in Inventories | |||||
Change in Payable / Accrued Expenses | |||||
Cash from Operating Activities | -8.53 | -6.7 | -2.98 | -1.29 | 1.04 |
Capital Expenditures | -0.831 | -1.76 | -2.05 | -1.09 | -0.863 |
Purchase of Fixed Assets | |||||
Purchase / Acquisition of Intangibles | |||||
Other Investing Cash Flow Items | 0.022 | 0.003 | 0.003 | 0.008 | 0.026 |
Acquisition of Business | |||||
Other Investing Cash Flow | |||||
Cash from Investing Activities | -0.809 | -1.76 | -2.04 | -1.08 | -0.837 |
Financing Cash Flow Items | -0.49 | -1.72 | -0.692 | -0.741 | -0.853 |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 2.43 | 17.7 | -0.192 | 0.91 | -1.51 |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | -6.94 | 9.19 | -5.26 | -1.76 | -1.3 |